Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 9
Submit an article Journal homepage
162
Views
6
CrossRef citations to date
0
Altmetric
Theme: General - Review

Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran

Vijay A DoraiswamySarver Heart Center, University of Arizona, Tucson, AZ,USA
,
Marvin J SlepianSarver Heart Center, University of Arizona, Tucson, AZ,USA
,
Martin G GesheffSinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA
,
Udaya S TantrySarver Heart Center, University of Arizona, Tucson, AZ,USA
&
Paul A GurbelSarver Heart Center, University of Arizona, Tucson, AZ,USACorrespondence[email protected]
Pages 1259-1267 | Published online: 10 Jan 2014

References

  • Lip GY, Huber K, Andreotti F et al. Consensus Document of European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary – a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 31, 1311–1318 (2010).
  • Rubboli A, Halperin JL, Airaksinen KE et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann. Med. 40, 428–436 (2008).
  • Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev. Cardiovasc. Ther. 2, 535–545 (2004).
  • Merlini PA, Ardissino D, Oltrona L et al. Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 15, 1675–1679 (1995).
  • Hoffmeister HM, Ehlers R, Buttcher E et al. Relationship between minor myocardial damage and inflammatory acute-phase reaction in acute coronary syndromes. J. Thromb. Thrombolysis. 15, 33–39 (2003).
  • Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90, 61–68 (1994).
  • Golino P, Ravera A, Ragni M et al. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation 108, 2864–2869 (2003).
  • Brummel-Ziedins K, Undas A, Orfeo T et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J. Thromb. Haemost. 6, 104–110 (2008).
  • Li YH, Teng JK, Tsai WC et al. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 33, 1543–1544 (1999).
  • Merlini PA, Ardissino D, Bauer KA et al. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 17, 1325–1330 (1997).
  • Antman EM, Braunwald E. Acute myocardial infarction. In: Heart Disease (5th Edition). Braunwald E (Ed.). WB Saunders, Philadelphia, PA, USA, 1773–1775 (1997).
  • Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99, 1053–1059 (2002).
  • Winn MJ, Jain K, Ku DD. Argatroban and inhibition of the vasomotor actions of thrombin. J. Cardiovasc. Pharmacol. 22, 754–760 (1993).
  • Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 121, 569–583 (2010).
  • Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 125, 1276–1287 (2012).
  • Roe MT, Armstrong PW, Fox KA et al. TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367, 1297–1309 (2012).
  • Gurbel PA, Erlinge D, Ohman EM et al. TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308, 1785–1794 (2012).
  • Cohen M, Adams PC, Parry G et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 89, 81–88 (1994).
  • Williams MJ, Morison IM, Parker JH, Stewart RA. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J. Am. Coll. Cardiol. 30, 364–369 (1997).
  • Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 98, 1064–1070 (1998).
  • Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur. Heart J. 27, 519–526 (2006).
  • Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98, 1597–1603 (1998).
  • Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334, 1084–1089 (1996).
  • Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339, 1665–1671 (1998).
  • Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 347, 969–974 (2002).
  • Van Es RF, Jonker JJ, Verheugt FW et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360, 109–113 (2002).
  • Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903–1912 (2006).
  • Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360, 2066–2078 (2009).
  • De Caterina R, Husted S, Wallentin L et al.; Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J. Am. Coll. Cardiol. 59, 1413–1425 (2012).
  • Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb. Res. 127(Suppl. 2), S5–S12 (2011).
  • Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789–797 (2003).
  • Alexander JH, Becker RC, Bhatt DL et al.; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119, 2877–2885 (2009).
  • Alexander JH, Lopes RD, James S et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365m, 699–708 (2011).
  • Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, Phase II trial. Lancet 374, 29–38 (2009).
  • Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. ATLAS ACS 2–TIMI 51 Investigators. N. Engl. J. Med. 366, 9–19 (2012).
  • van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116–1127 (2010).
  • Wienen W, Stassen JM, Priepke H et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb. Haemost. 98, 155–162 (2007).
  • Sanford M, Plosker GL. Dabigatran etexilate. Drugs 68, 1699–1709 (2008).
  • Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).
  • Oldgren J, Budaj A, Granger CB et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, Phase II trial. Eur. Heart J. 32, 2781–2789 (2011).
  • Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. 172, 397–402 (2012).

Website

  • FDA Drug information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s009lbl.pdf. (Accessed on 27 November 2012)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.